Calidi refiles FY2023 financials to reflect 1-for-10 reverse stock split

Calidi Biotherapeutics, Inc.

1-for-10 reverse stock split effective July 15, 2024, retroactively applied to FY2023 statements.
Exhibits incorporated by reference from December 12, 2024 S-1; no change to non-split information.
All other 2023 Annual Report information remains unchanged.

item 8.01 item 9.01

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-001711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.